[Magnesium: current studies--critical evaluation--consequences].

T Meinertz

Home/Archive/PubMed

PubMed · 9064959

[Magnesium: current studies--critical evaluation--consequences].

T Meinertz

View original source ↗Export metadata ↓

Abstract

The therapeutic efficacy of magnesium has been studied during recent years in a number of cardiovascular diseases: supraventricular and ventricular arrhythmias (multifocal atrial tachycardia, Torsade de pointes-tachycardia, glycoside-associated arrhythmias, sustained ventricular tachycardia), acute myocardial infarction, heart failure and arterial hypertension. Although only a few of these arrhythmias were studied under controlled conditions, the therapeutic efficacy of intravenous magnesium given in a high dose in these arrhythmias seems to be established. By contrary, the efficacy of magnesium in acute myocardial infarction, congestive heart failure and arterial hypertension remains controversial up to now. Magnesium cannot be regarded as standard therapy for example for patients with acute myocardial infarction.

Explore related subjects

Anti-Arrhythmia Agents Clinical Trials as Topic Dose-Response Relationship, Drug Electrocardiography Heart Conduction System Humans Infusions, Intravenous Magnesium Myocardial Infarction Tachycardia, Supraventricular Tachycardia, Ventricular English Abstract Journal Article Review

Keep this discovery

Explore connections, maps & timelines

BibTeX RIS

T Meinertz. 1996. [Magnesium: current studies--critical evaluation--consequences].. https://pubmed.ncbi.nlm.nih.gov/9064959/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2003

Atrial fibrillation in heart failure: epidemiology, pathophysiology, and rationale for therapy.

Heart failure (HF) affects almost 5 million patients in the United States and is a leading cause of morbidity and mortality. Atrial fibrillation (AF), like HF, affects millions of patients and markedly increases in prevalence with age. As the US population ages, the number of patients afflicted with HF and AF will continue to grow. HF with preserved ejection fraction is particularly common in the elderly population. The prevalence of AF in patients with HF increases from <10% in those with New York Heart Association (NYHA) functional class I HF to approximately 50% in those with NYHA functional class IV HF. The pathophysiologic changes that occur in patients with HF and AF are complex and incompletely understood. Alterations in neurohormonal activation, electrophysiologic parameters, and mechanical factors conspire to create an environment in which HF predisposes to AF and AF exacerbates HF. Mechanisms include atrial remodeling and tachycardia-induced myopathy. The development of AF in HF appears to independently predict death resulting from pump failure and total mortality. Although the currently available therapeutic options for AF in patients with HF are varied, their effect on prognosis remains unknown and is the subject of ongoing clinical trials. It will be critical to define and plan therapies specifically for those patients with AF, HF, and preserved ejection fraction in addition to the population with low ejection fraction that has dominated previous investigations.

Anti-Arrhythmia Agents↗

PubMed2003

Use of antiarrhythmics and implantable cardioverter-defibrillators in congestive heart failure.

As much as half of the mortality in patients with congestive heart failure (CHF) resulting from left ventricular systolic dysfunction is attributable to sudden cardiac death. Thus, the identification of risk and prevention of sudden death are important components of treating this population of patients. Antiarrhythmic drugs have been shown to be either neutral or harmful when studied in patients with prior myocardial infarction and impaired left ventricular function. Amiodarone, when studied in patients with CHF, may be of benefit. This benefit may be more pronounced in patients with nonischemic cardiomyopathy. Implantable cardioverter defibrillators (ICDs) are of clear benefit when used in the primary and secondary prevention of sudden death in selected populations. Studies soon to be completed should clarify the role of the cardioverter-defibrillator in patients with CHF. Antiarrhythmic medications are often used in conjunction with ICDs for a variety of reasons. However, these drugs have the potential to adversely affect defibrillator function, and knowledge of these effects is important when using this strategy.

Anti-Arrhythmia Agents↗

PubMed2003

[Tachyarrhythmias--when rapid pace is pathological].

Tachycardias are classified as supraventricular and ventricular tachycardias. Supraventricular and ventricular tachycardias may occur as a complication of almost any underlying cardiac disease and many extracardiac causes. In addition, patients without any detectable structural heart disease may present with these arrhythmias. In this overview, we discuss the clinical presentations, the pathophysiological mechanisms and the therapeutical strategies in patients with tachyarrhythmias.

Anti-Arrhythmia Agents↗